Function Therapeutics receives Phase 1 SBIR Award from NIH (NHLBI)

Function Therapeutics has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI)

https://reporter.nih.gov/project-details/10699379

The grant is titled “Allosteric Modulation of PAR1 for the Treatment of Sickle Cell Disease”. This project focuses on the development of the new parmodulin class of anti-inflammatory compounds, and their testing in models of this blood and vascular disease that can make daily life extremely challenging (and dangerous) for hundreds of thousands worldwide. This project is a collaboration with Dr. Erica Sparkenbaugh at the University of North Carolina, whose lab has performed important work to demonstrate the protective ability of parmodulins in vascular disease.

#parmodulin #sicklecelldisease #inflammation